Tech Support


This line is for technical support.
For General Enquiries please click General Contact


WEBINAR: 3D In Vitro Drug Discovery

When and How to Use Tumor Organoids

Thursday February 27 - 3am/10am/5pm ET

Join Dr Rajendra Kumari to explore the best time to implement tumor organoids in your drug development programs. Review the key differences between 3D in vitro systems, including organoids and primary cells, and how to select the right 3D in vitro platform based on model features, benefits, and limitations.

Cambridge, UK Symposium - Tuesday March 17th

Oncology and Immuno-Oncology Drug Discovery: Taking Preclinical Candidates to the Next Level

Join CrownBio at our annual UK symposium, focussing on the new targets, methods, and models which are enhancing both preclinical development and oncology drug candidates. Hear from a range of speakers on the evolution of preclinical models and the new targets, including combination regimens, for next generation oncology and I/O agents.

ON DEMAND WEBINAR: 3 Strategies to Identify Clinically Predictive Biomarkers in the Preclinical Space

Join Mike Batey to learn how to apply systems biology in early stage drug development for biomarker discovery and validation. Review 3 case studies exploring novel strategies to identify and utilize biomarkers using translational preclinical models, including using in vitro models to uncover genetic signatures of response and in vivo PDX to dissect drug MoA and guide clinical trial design.

NEW WHITE PAPER: Applications of HUB Tumor Organoids in Oncology Drug Development

Learn more about PDX-derived tumor organoids (PDXO) developed using HUB protocols, as robust in vitro models to improve the predictivity and speed of preclinical drug discovery. Review the main applications of 3D PDXO including large-scale drug screening, in vivo model selection, and in silico drug discovery.

ON DEMAND WEBINAR: Reversing Hypertriglyceridemia and Hepatic Steatosis in Dysmetabolic NHPs with a Controlled-Release Mitochondrial Protonophore (CRMP)

Presented by Dr Leigh Goedeke, Yale School of Medicine this webinar details using spontaneous NHP models of NAFLD and metabolic syndrome to assess a controlled-release mitochondrial protonophore (CRMP). Explore proof-of-concept data from these clinically relevant models, supporting the development of novel liver-targeted mitochondrial uncouplers to treat human NASH and T2D.

NEW WHITE PAPER: How to Detect, Characterize, and Evaluate CAR-T Cell Therapies

Learn how to optimize preclinical model selection for CAR-T cell therapy assessment through understanding available model advantages and limitations, alongside your study aims. Explore a multiparameter imaging and analysis platform for improved CAR-T cell detection and characterization to enhance clinical development and success.

ON DEMAND WEBINAR: Demonstrating Clinical Relevance in 3D In Vitro Modeling with HUB Organoids

Presented by Dr Sylvia Boj, Hubrecht Organoid Technology this webinar reviews the development and application of HUB Organoids. Explore the many advantages of HUB Organoids within 3D in vitro modeling, including direct clinical relevance and immuno-oncology applications.

NEW WHITE PAPER: How to Assess Immunotherapy Toxicity using NHPs

Learn more about NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. Explore the robust data these studies generate in a rapid, flexible, and cost-effective manner to assess immunotherapy safety and de-risk future clinical trials.

NEW WHITE PAPER! HUB Organoid Technology: Advantages in 3D In Vitro Modeling

Review the breakthrough discoveries leading to the development of HUB Organoids. Explore the key features of these 3D in vitro models including organ morphology recapitulation, stability, genomic superiority, and long-term culture, as well as their main utilities in research and development.

WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical Model

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.


Models of Obesity


CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More


Oncology Databases


Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More


Diabetes Models


Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

February 25, 2020

Using Organoids to Understand Colorectal Cancer Mechanisms and Development

Learn how healthy tissue and tumor-derived organoids are used to uncover disease mechanisms, here shining a light on the link between colorectal cancer and vitamin D deficiency.

Read More

February 25, 2020

Using Organoids to Understand Colorectal Cancer Mechanisms and Development

Learn how healthy tissue and tumor-derived organoids are used to uncover disease mechanisms,...

Read More

February 20, 2020

Identify Predictive Biomarkers Using Translational Preclinical Models

Explore a variety of methods to identify predictive biomarkers using a range of translational...

Read More

February 18, 2020

Using Liver-Targeted Mitochondrial Uncoupling to Resolve Fatty Liver Disease

Explore how liver-targeted mitochondrial uncoupling is resolving fatty liver disease in...

Read More

February 13, 2020

Targeting KRAS: Finally Drugging the Undruggable?

Targeting KRAS - As promising clinical trial data emerges for KRAS G12C inhibitors, we review...

Read More

February 11, 2020

huPBMC Humanized Mouse Models: De-Risking Graft versus Tumor (GvT) Effects Through a Co-Culture Donor Selection Assay

Explore how to use a donor selection assay to limit the chances of graft vs tumor (GvT) effects...

Read More

Upcoming Events

February 27, 2020

Webinar: 3D In Vitro Drug Discovery: When and How to Use Tumor Organoids

March 2-4, 2020

ESMO Targeted Anticancer Therapies Congress 2020

Paris, France

March 9, 2020

PBSS Preclinical Models to Guide Therapeutic Development in Oncology Symposium

San Francisco

March 9-12, 2020

Immuno-Oncology Summit Europe

London, UK

March 15-19, 2020

SOT 59th Annual Meeting and ToxExpo

Anaheim, CA | Booth #1734